

To: Methvin, Stacy P SCC-DCA <Stacy.Methvin@shell.com>;
Simpson, Edward J SCC-DCA/2
<Edward.Simpson@shell.com>; Snyder, Phil J SCC-DXX/9
<phil.snyder@shell.com>; Sykes, Paul B SCC-DCS/23
<Paul.Sykes@shell.com>; Williams, Elizabeth J SCAI-
DCS/22 <elizabeth.williams@shell.com>
From: Clegg, Patsy M SCC-DCS/22
</O=SHELL/OU=MSXSCC/CN=RECIPIENTS/CN=PH197432>
Cc: Cagen, Stuart Z SHLOIL-SHOIL-SHS
<stuart.cagen@shell.com>; Tsai, Shan P SHLOIL-SHS
<Shan.Tsai@shell.com>; Semmler, Klaus K DSC-DCS/235
<klaus.semmler@shell.com>
Bcc:
Received Date: 2007-04-10 18:36:41 GMT
Subject: FOR INFORMATION: Shanghai Health Study, Amendment 4
signed

Stacy signed amendment 4 to the Shell/API contract that supports the Shanghai Health Study.
This amendment increases the budget by 9.1M; 1.6M is Shell's share.

I have faxed a copy to API and have put one of the originals in overnight mail to API and the other
original on file in HSSE.

The API Executive Committee will be meeting via telecon on Wednesday, April 11, to consider
approval of advance funding for the laboratory until a new contract can be put in place and
approval of CinPathogen as the contracting entity. See attached issue paper.

Pats Clegg
Product Steward
Shell Chemical LP
One Shell Plaza, 910 Louisiana, Houston, TX 77002-4916

Tel: +1 713 241 2521 **Fax:** 3325
Email: patsy.clegg@shell.com
Internet: <http://www.shell.com/chemicals>

Attachments:

04112007_SHS_Issue_Paper.ZIP